Members S - Z
S
Sandoz International GmbH
ScheBo Biotech AG
ScheBo®o Biotech AG is an innovative pharmaceutical biotech company that is active in the fields of drug development in oncology and the development, production and marketing of diagnostics. ScheBo®o Biotech AG has recently launched the Tumor M2-PK stool test for colorectal cancer screening.
www.schebo.de
Scil Technology GmbH
Scil Technology is developing regenerative therapeutics for orthopaedics and dentistry. The products are based on human, highly specific, proprietary growth factors combined with a wide variety of biomaterials. After local product application the growth factors stimulate bone or cartilage regrowth, so that while the material is gradually absorbed by the body it is replaced by the natural tissue.
www.scil.com
SCT Spinal Cord Therapeutics GmbH
SCT Spinal Cord Therapeutics GmbH stands for pioneering the therapy of acute and chronic Spinal Cord Injuries (SCI) with its proprietary technology platform: the Regeneration Promoting Treatment (RPT). As first application of RPT SCT Spinal Cord Therapeutics GmbH is focusing on the clinical development of the Orphan Drug Cordaneurin® for the treatment of acute SCI.
www.sctpx.com
sequiserve GmbH
Sequiserve is a customized DNA sequencing service since 1994. Our main focus is on quality, speed and individual advice for all questions concerning DNA-sequencing.
www.sequiserve.de
Silence Therapeutics AG
Silence Therapeutics plc is a leading European RNAi company. RNA interference (RNAi), a Nobel Prize winning technology, is one of the most exciting areas of drug discovery today as it can selectively "silence" genes linked to the onset of disease, thus leading to the creation of a new class of therapeutic products, RNAi therapeutics.
www.silence-therapeutics.com
Sirion GmbH
SIRION offers tools and services for RNAi expression and solutions for customized adenovirus-mediated gene delivery. SIRION´s proprietary Q-tech technology enables efficient RNAi driven gene silencing without siRNA transfection.
Based on Q-tech technology customized HTS-compatible cells are available for various gene silencing assays and functional testing of miRNAs.
www.sirion-biotech.de
SIRS-Lab GmbH
SIRS-Lab is focused on the identification, development and commercialization of novel, proprietary biomarkers and IVD systems for inflammatory disorders.
Our core expertise includes critical care medicine, assay design, assay development, bio-banking and CE-compliant analysis of clinical samples.
www.sirs-lab.de
Sloning Biotechnology GmbH
Sloning BioTechnology GmbH is a Biotech company, which has developed a novel, fully automated method for the production of synthetic genes: Slonomics™.
Apart from producing customised genes, Sloning is especially focused on the production of gene variants and whole mutant libraries (SlonoMax™).
www.sloning.com
SOVICELL GmbH
Spherotec GmbH
Spherotec offers an innovative, therapeutically relevant strategy in all stages of oncological drug profiling: the 3D-microtumor like spheroid model. Its exceptional human tissue similarity facilitates predictive drug testing with respect to efficacy; cell toxicity; drug penetration into the tumor and pharmacodynamics. Furthermore the optimal clinical indication spectrum of drug candidates can be identified.
www.spherotec.com
SuppreMol GmbH
SuppreMol GmbH is unlocking the therapeutic potential of Fc-Receptors to interfere with autoimmune diseases. The lead product is a soluble Fc-Receptor interacting with an early step of the disease. SuppreMol is developing its product first in an orphan drug indication bridging to block buster markets of SLE and Rheumatoid Arthritis.
www.suppremol.com
SWFG mbH
Sygnis Pharma AG
T
t2cure GmbH
t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases like myocardial infarction or peripheral artery occlusive disease.
www.t2cure.com
Targos Molecular Pathology GmbH
Targos focuses on the application, discovery and development of predictive biomarkers in oncology. Targeted therapies in oncology usually require biomarker guidance in development and clinical application for ethical, economic and regulatory reasons. Targos combines molecular pathology expertise with highly standardized analytics and applies strict project and quality management to provide the international pharma and diagnostic industry with customer-oriented premier biomarker services. In addition, Targos is active in the definition of proprietary biomarkers.
www.targos-gmbh.de
Technology Consulting Dr. Roswitha Gropp
Technologiepark Heidelberg GmbH
The Heidelberg Technology Park (founded 1985) is an international Life Sciences Park. The Park offers 50.000 sqm lab and office space. With 75 companies and research insti-tutes, about 200 Associated Members and an international network of cooperation the Park is forming the center of the Heidelberg BioCluster.
www.technologiepark-hd.de
Techno Venture Management GmbH
Techno Venture Management (TVM), is one of the first venture capital firms formed in Germany, and an early entrant into the US market in 1986. Since inception TVM has raised over 1.2 billion in five fund generations. TVM funds have made investments in more than 220 information technology and life science companies where innovation, effective management and sound financial backing have enormous impact on company growth.
www.tvmvc.de
Tidona Consulting GmbH
Tidona Consulting advises entrepreneurs and investors in the field of life science. We are focused on business planning, business development and consolidation. At www.LSIS.de our customers have direct access to all relevant life science information - world-wide and up-to-date.
www.tidonaconsulting.com
TVM Capital GmbH
U
U3 Pharma AG
U3 Pharma is a biopharmaceutical company focusing on the development of novel anti-cancer therapeutics. The company is centered on expertise in translational medicine and is creating the next generation of targeted therapeutics that utilize the inhibition of functional drivers of cancer cell progression. Founded by Axel Ullrich in 2001, U3 Pharma currently compoys 29 people at its facilities in Munich, Germany.
www.U3pharma.com
UBS Wealth Management AG
UBS is one of the world"s leading financial firms, serving a discerning global client base. As an organization, it combines financial strength with an international culture that embraces change. UBS is present in all major financial centers worldwide. It has offices in 50 countries.
www.ubs.com
V
Vakzine Projekt Management GmbH
VPM is a development company for vaccines and related immunologically active compounds.
With a consortium of partners VPM develops a 2nd generation interferon for multiple sclerosis, allogeneic therapeutic vaccines against cancer (prostate, renal cell carcinoma, melanoma), and vaccines against tuberculosis, malaria, and cytomegalo virus.
VPM is funded by BMBF (Bundesministerium für Bildung und Forschung) and has been set up to form a bridge from academic research to commercial application.
www.vakzine-manager.de
Vasopharm GmbH
vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the biovailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS 203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.
www.vasopharm.com
VIROLOGIK GmbH
VISCARDI AG
VISCARDI is an independent full service investment bank focusing on financing transactions and mergers & acquisitions for small and mid cap companies. VISCARDI structures innovative financing solutions for companies from the health care/life sciences, technology and other selected industries, including real estate, retail and location-based services.
Moreover, VISCARDI offers equity research and designated sponsoring services to its institutional clients.
www.viscardi.com
Dr. Volker Vossius
The law firm of DR. VOLKER VOSSIUS is a partnership of patent attorneys and attorneys at law offering comprehensive services in all intellectual property matters to national and international clients in the fields of biotechnology, chemistry, pharmacy, engineering and electronics. Furthermore, the firm renders reviews of patent portfolios and opinions for due diligence procedures for investors and companies.
www.vovo.de
W
Wacker Biotech GmbH
Wacker Biotech GmbH is an experienced full-service contract manufacturer of biopharmaceuticals derived from microbial systems and offers proprietary technologies like its E. coli-based secretion system. The Jena-based Wacker Biotech GmbH is a wholly-owned WACKER subsidiary.
www.wacker.com
Weitnauer Rechtsanwälte, Wirtschaftsprüfer, Steuerberater
www.weitnauer.net
WEITNAUER has focused since its foundation in 1995 on Venture Capital, with particular emphasis on biotechnology (e.g. editing of the yearly bioplus-study). Broad range of consulting services, comprising investment agreements, stock options, licence/cooperation agreements and all modes of exit (M&A/IPO).
WestLB AB
WestLB is a new type of universal bank founded on it"s partnership with the savings banks and our background as a European commercial bank. Our Life Sciences Teams in the Corporate and Investment Banking units offer innovative products and competent advice to our clients in the Life Sciences sector.
www.westlb.de
Wilex AG
Wilex is developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well tolerated treatment and enhance patients" quality of life.
www.wilex.com
Z
Zedira GmbH
The core biotech company located in Darnstadt, Germany, has made a commitment to Celiac Disease and Transglutaminase. Production and distribution of speciality reagents for basic research as well as the recently characterized diagnostic marker for Celiac Disease (neuronal transglutaminase) are rounded off by the development of a drug, which shall help to improve patient's quality of life.
www.zedira.com
Zentaris GmbH
Zimmermann & Partner
Main areas of expertise of the Intellectual Property law firm Zimmerman & Partner are biochemistry, genetic engineering, pharmacy, and chemistry.
Zimmermann & Partner is based in Munich with offices in Berlin and the Rhein-Main area of Germany. The firm offers the full range of services in the fields of Intellectual Property, especially in regards to license law, patent and trademark law as well as contract law – for example CDAs and cooperation agreements.
www.zimpat.com